Timothy Lederer
Family · Abingdon, MDNPI 1033695960
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,659, more than ten times the $35 reported in 2021. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$929
- Novo Nordisk$537
- AbbVie$367
- Amgen$337
- Pfizer$267
- Johnson & Johnson$242
- plus $3K from 38 others
What the payments were for
- Food & beverage$5,42099%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,474 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $12,051 |
| Oxcarbazepine | 14 | $1,366 |
| Levetiracetam | 22 | $988 |
| Olanzapine | 16 | $646 |
| Atorvastatin Calcium | 22 | $531 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $479 |
| Losartan Potassium | 36 | $477 |
| Tamsulosin Hcl | 14 | $402 |
| Ketoconazole | 12 | $385 |
| Gabapentin | 18 | $352 |
| Lisinopril | 36 | $279 |
| Rosuvastatin Calcium | 17 | $270 |
| Levothyroxine Sodium | 15 | $187 |
| Amlodipine Besylate | 46 | $167 |
| Ibuprofen | 13 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $57 | $12,05113 claims |
| Lilly USA, LLCOlanzapine | $222 | $64616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Abingdon
- Geneva AcuffAbingdon$9K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Ariana ChaoLutherville$85K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.